Sunovion Pharmaceuticals
Pharmaceutical Manufacturing • 
Marlborough, Massachusetts, United States • 501-1000 Employees
Company overview
| Headquarters | 84 Waterford Dr, Marlborough, MA 01752, US |
| Phone number | +15084816700 |
| Websites | |
| NAICS | 3254 |
| SIC | 283 |
| Keywords | Central Nervous System |
| Founded | 2010 |
| Employees | 501-1000 |
| Socials |
Key Contacts at Sunovion Pharmaceuticals
Matthew Getman
Associate Director, Compliance & Ethics
Yu-Luan Chen
Executive Director, Global Bioanalytical Sciences
David Crandall
Director, Clinical Development, Cns - Neurology
Thao Nguyen
Sr. National Account Director, Long-Term Care Market Access
Maureen Sheltry
Executive Director, Advocacy Relations
Pamela Krengel
Executive Director, Market Access Marketing, Training And Patient Experience
Eric J. Pappert
Executive Medical Director
Jim Shepherd
National Account Director, Trade
Maureen Kincaid
Director, Business Insights
Dorothy Collins
Associate Director, Customer Marketing
Sunovion Pharmaceuticals Email Formats
Sunovion Pharmaceuticals uses 4 email formats. The most common is {first initial}.{last name} (e.g., j.doe@sunovion.com), used 77.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@sunovion.com | 77.7% |
{first name}.{last name} | john.doe@sunovion.com | 17% |
{2char} | {2char}@sunovion.com | 1.8% |
{first initial}{last name}.{last name} | jdoe.doe@sunovion.com | 1.8% |
About Sunovion Pharmaceuticals
This page is no longer active or monitored. We are now Sumitomo Pharma America (SMPA), a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need. See pinned post for our new page and follow us!⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀ ==== Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. The Company has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with serious neurological and psychiatric conditions. Sunovion’s track record of discovery, development and commercialization of important therapies has included Latuda® (lurasidone HCI), Aptiom® (eslicarbazepine acetate) Lonhala® Magnair® (glycopyrrolate), and, most recently, KYNMOBI® (apomorphine HCI) sublingual film. Headquartered in Marlborough, MA Sunovion is an indirect, wholly owned subsidiary of Sumitomo Pharma Co., Ltd. Sunovion Pharmaceuticals Canada, Inc., based in Mississauga, Ontario, is a wholly-owned direct subsidiary of Sunovion Pharmaceuticals Inc. Find more information at www.sunovion.com and connect on Twitter and Facebook @Sunovion. LATUDA is a registered trademark of Sumitomo Pharma Co., Ltd. APTIOM is used under license from BIAL. KYNMOBI is a registered trademark of Sunovion Pharmaceuticals Inc. LONHALA MAGNAIR is a registered trademarks of Sunovion Pharmaceuticals Inc. © 2023 Sunovion Pharmaceuticals Inc. To view our community guidelines, see here: bit.ly/3CozDLX
Sunovion Pharmaceuticals revenue & valuation
| Annual revenue | $600,000,000 |
| Revenue per employee | $621,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $1,920,000,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 501-1000
Seniority
Employees
Employees by Department
Sunovion Pharmaceuticals has 604 employees across 15 departments.
Departments
Number of employees
Canada
Italy
SpainFrequently asked questions
4.8
40,000 users
